Free Trial
NASDAQ:ARVN

Arvinas Q3 2023 Earnings Report

Arvinas logo
$7.73 -0.03 (-0.39%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$7.72 -0.01 (-0.06%)
As of 08/29/2025 07:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arvinas EPS Results

Actual EPS
-$1.18
Consensus EPS
-$1.58
Beat/Miss
Beat by +$0.40
One Year Ago EPS
-$1.24

Arvinas Revenue Results

Actual Revenue
$34.60 million
Expected Revenue
$39.58 million
Beat/Miss
Missed by -$4.98 million
YoY Revenue Growth
+14.20%

Arvinas Announcement Details

Quarter
Q3 2023
Time
Q3 2023 Earnings Release
Conference Call Date
Tuesday, November 7, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Arvinas' Q3 2025 earnings is scheduled for Wednesday, October 29, 2025, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Arvinas Earnings Headlines

Arvinas to Participate in Upcoming Investor Conferences
Arvinas, Inc. (NASDAQ:ARVN) Stake Jumps 194% at XTX Topco
The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.tc pixel
Arvinas, Inc. (NASDAQ:ARVN) Stake Jumps 194% at XTX Topco
Oppenheimer Remains a Hold on Arvinas Holding Company (ARVN)
See More Arvinas Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Arvinas? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arvinas and other key companies, straight to your email.

About Arvinas

Arvinas (NASDAQ:ARVN), a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

View Arvinas Profile

More Earnings Resources from MarketBeat